| Literature DB >> 30284214 |
Su Golder1, Stephanie Chiuve2, Davy Weissenbacher3, Ari Klein3, Karen O'Connor3, Martin Bland4, Murray Malin2, Mondira Bhattacharya2, Linda J Scarazzini2, Graciela Gonzalez-Hernandez3.
Abstract
INTRODUCTION: Adverse effects of medications taken during pregnancy are traditionally studied through post-marketing pregnancy registries, which have limitations. Social media data may be an alternative data source for pregnancy surveillance studies.Entities:
Mesh:
Year: 2019 PMID: 30284214 PMCID: PMC6426821 DOI: 10.1007/s40264-018-0731-6
Source DB: PubMed Journal: Drug Saf ISSN: 0114-5916 Impact factor: 5.606
Fig. 1Workflow of tweet collection, tweet annotation, and timeline analysis for selecting the birth defects (case) cohort
Birth defects by the Medical Dictionary for Regulatory Activities (MedDRA)
| MedDRA sub-class of congenital, familial, and genetic disorders | Frequency |
|---|---|
| Musculoskeletal and connective tissue disorders congenital | 63 |
| Cardiac and vascular disorders congenital | 46 |
| Gastrointestinal tract disorders congenital | 45 |
| Chromosomal abnormalities and abnormal gene carriers | 21 |
| Neurological disorders congenital | 13 |
| Renal and urinary tract disorders congenital | 5 |
| Eye disorders congenital | 3 |
| Respiratory disorders congenital | 3 |
| Skin and subcutaneous tissue disorders congenital | 2 |
| Blood and lymphatic system disorders congenital | 2 |
| Hepatobiliary disorders congenital | 1 |
| Reproductive tract and breast disorders congenital | 1 |
| Ear and labyrinth disorders congenital | 1 |
The sum of the frequencies is slightly greater than the number of cases; this is because, in some of the individual cases, the child had multiple birth defects and the defects belonged to different sub-classes
Characteristics of the cases and controls among women who gave birth
| Characteristics | Cases ( | Controls ( | |
|---|---|---|---|
| Age, years | |||
| Median age (IQR) | 23 (20–28) | 21 (19–23) | 0.0001 |
| Mean age (range) | 25 (17–42) | 22 (16–37) | < 0.0001 |
| Women < 30, % | 68 | 66 | 0.004 |
| Women < 35, % | 80 | 70 | 0.04 |
| Missing data on age, % | 14 | 28 | 0.0008 |
| Race/ethnicity, % | |||
| Caucasian | 61 | 52 | < 0.001 |
| Black | 11 | 26 | |
| Hispanic | 6 | 11 | |
| Asian | 2 | 3 | |
| Other | 2 | 3 | |
| Missing data on race | 16 | 6 | |
| Place of residence, % | |||
| USA | 66 | 77 | 0.04 |
| UK | 16 | 8 | |
| Canada | 4 | 3 | |
| Other | 2 | 3 | |
| Missing data on place of residence | 6 | 9 | |
IQR interquartile range
ap values were estimated using the chi-squared test
Fig. 2Age of the women who gave birth to a baby with a birth defect (cases) and without a birth defect (controls). CM women who gave birth to a baby with a malformation
Medication intake, timing, and type in the cases and controls
| Cases, % ( | Controls, % ( | ||
|---|---|---|---|
| Medication use | |||
| Any medication use during pregnancy | 35 (68/196) | 17 (34/196) | 0.0001 |
| Timing of medication intake among women taking medicationsb | |||
| Any medication use during first trimesterd | 42 (23/55) | 23 (7/31) | 0.1 |
| Any medication use during second trimesterd | 34 (22/65) | 38 (12/32) | 0.7 |
| Any medication use during third trimester | 63 (43/68) | 65 (22/34) | 0.9 |
| Type of medication intake among women taking medicationsb | |||
| ‘Probably safe’ medications onlyc | 62 (42/68) | 65 (22/34) | 0.9 |
| At least one ‘potentially risky’ medicationc | 21 (14/68) | 18 (6/34) | |
| At least one unclassified medicationc | 18 (12/68) | 18 (6/34) | |
The ‘probably safe’ category consisted of A, B1, and B2 classifications and the ‘potentially risky’ category consisted of B3, C, D, and X as per the Australian categorization system (https://www.tga.gov.au/prescribing-medicines-pregnancy-database)
ap values were estimated using the chi-squared test
b‘Among women taking medications’ means the denominator used was only those women who reported taking any medication as opposed to the whole group of women
cMultiple medications were taken by some women and some medications were taken more than once
dFor some women, data from posts were missing in the first and second trimester
Percentage of instances of intake of ‘probably safe’, ‘potentially risky’, and ‘unclassified’ medications
| Instances in cases, % ( | Instances in controls, % ( | ||
|---|---|---|---|
| First trimester, | 27 | 8 | |
| ‘Probably safe’ medication | 67 (18/27) | 63 (5/8) | 0.70 |
| ‘Potentially risky’ medication | 22 (6/27) | 13 (1/8) | |
| ‘Unclassified’ medication | 11 (3/27) | 25 (2/8) | |
| Second trimester, | 39 | 14 | |
| ‘Probably safe’ medication | 61 (24/39) | 64 (9/14) | 0.75 |
| ‘Potentially risky’ medication | 15 (6/39) | 21 (3/14) | |
| ‘Unclassified’ medication | 23 (9/39) | 14 (2/14) | |
| Third trimester, | 60 | 26 | |
| ‘Probably safe’ medication | 73 (44/60) | 77 (20/26) | 0.93 |
| ‘Potentially risky’ medication | 15 (9/60) | 15 (4/26) | |
| ‘Unclassified’ medication | 12 (7/60) | 8 (2/26) | |
| Total pregnancy, | 126 | 48 | |
| ‘Probably safe’ medication | 68 (86/126) | 71 (34/48) | 0.97 |
| ‘Potentially risky’ medication | 17 (21/126) | 17 (8/48) | |
| ‘Unclassified’ medication | 15 (19/126) | 13 (6/48) |
The ‘probably safe’ category consisted of A, B1, and B2 classifications and the ‘potentially risky’ category consisted of B3, C, D, and X as per the Australian categorization system (https://www.tga.gov.au/prescribing-medicines-pregnancy-database)
aFisher’s exact t test
Odd ratios (95% confidence intervals) [ORs (95% CIs)] for birth defects by various demographic and lifestyle factors
| Variable | OR (95% CI) [logistic regression estimates] | |||
|---|---|---|---|---|
| Univariable, unadjusted | Multivariable, adjusted | |||
| Age (per year) | 1.10 (1.05–1.15) | < 0.001 | 1.09 (1.03–1.15) | 0.002 |
| Medication use | ||||
| Yes | 2.53 (1.58–4.06) | < 0.001 | 2.34 (1.24–4.44) | 0.004 |
| No | 1.0 (ref) | 1.0 (ref) | ||
| Ethnicity | ||||
| Caucasian | 1.0 (ref) | < 0.001 | 1.0 (ref) | 0.008 |
| Black | 0.37 (0.21–0.65) | 0.40 (0.21–0.79) | ||
| Hispanic | 0.57 (0.27–1.17) | 0.86 (0.36–2.04) | ||
| Asian | 0.68 (0.18–2.60) | 0.83 (0.25–1.55) | ||
| Other | 0.68 (0.18–2.60) | 0.80 (0.19–3.48) | ||
| Missing | 2.27 (1.11–4.62) | 3.42 (1.25–9.40) | ||
| Place of residence | ||||
| USA | 1.0 (ref) | 0.01 | 1.0 (ref) | 0.3 |
| UK | 2.28 (1.19–4.36) | 1.97 (0.85–4.57) | ||
| Canada | 1.89 (0.60–5.90) | 1.06 (0.22–5.03) | ||
| Other | 0.20 (0.02–1.65) | 0.24 (0.01–4.43) | ||
| Missing | 1.73 (0.90–3.35) | 1.69 (0.69–4.11) | ||
ref reference
| Social media data can provide information on medication intake and birth defects; however, the information obtained cannot replace pregnancy registries at this time. At present, these data are incomplete but may still be useful to supplement pregnancy registry data. |
| Future research is necessary to refine efforts and uses of social media data to support regulatory decision making regarding pregnancy outcomes with recently approved drugs used in women of child-bearing age. |